-
Most Recent
Search Results
240 results for DDRX
Analysis of Earnings Growth Makes Allscripts Healthcare Solutions (MDRX) a Sell
Allscripts Healthcare Solutions (NASDAQ:MDRX) is a $2.5 billion in market value component of the Health Care Technology GICS industry group where the current Portfolio Grader…
Analysis of Earnings Visibility Keeps Allscripts Healthcare Solutions (MDRX) a Sell
Allscripts Healthcare Solutions (NASDAQ:MDRX) is classified as a constituent of the 26 company Health Care Technology GICS industry group, which is a segment of the…
Falling Earnings Visibility Keep Allscripts Healthcare Solutions (MDRX) a Sell
Currently, Allscripts Healthcare Solutions (NASDAQ:MDRX) has a Sell using Louis Navellier’s methods for investing and his Portfolio Grader stock evaluator. This represents no change from…
Quant Score Metrics Restrict Allscripts Healthcare Solutions (MDRX) Ratings Upgrade to Hold
Allscripts Healthcare Solutions (NASDAQ:MDRX) is ranked as a Hold using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. MDRX has…
Earnings Visibility Hamper Allscripts Healthcare Solutions (MDRX) Rating
Allscripts Healthcare Solutions (NASDAQ:MDRX) ranks in the upper half of its industry group, Health Care Technology, and in the top 25% of its sector group,…
Sell Rating on Allscripts Healthcare Solutions (MDRX) Shares Kept
Allscripts Healthcare Solutions (NASDAQ:MDRX) is ranked as a Sell using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. The current…
Earnings Growth Keeps Allscripts Healthcare Solutions (MDRX) a Sell
Currently, Allscripts Healthcare Solutions (NASDAQ:MDRX) has a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier’s investing methodology. This represents no change from…
Sell Rating on Allscripts Healthcare Solutions (MDRX) Shares Kept
Allscripts Healthcare Solutions (NASDAQ:MDRX) is ranked as a Sell using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. The current…
Quant Score Analytics Keep Allscripts Healthcare Solutions (MDRX) Ratings Upgrade to Hold
Allscripts Healthcare Solutions (NASDAQ:MDRX) is ranked as a Hold using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. The shares…
Allscripts Healthcare Solutions (MDRX) Shares Raised to Hold
As one of the 781 companies in the GICS Health Care sector Allscripts Healthcare Solutions (NASDAQ:MDRX) is a member of the 24 company Health Care…
Micron Technology (MU) Earnings: Everything You Need to Know
Micron Technology (MU) has been on the losing end of a tough DRAM market all year long, but supply and demand for DRAM may have…
AMD Stock Could Be the Best Way to Play the AI Sector Right Now
For investors looking for top-notch chip makers to buy to play the surge in AI, AMD stock could be among the best bets to make…
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today?
Biodexa Pharmaceuticals stock is up on Tuesday with heavy trading of BDRX stock despite a lack of news from the company.
Why Is Biodexa (BDRX) Up 70% Today?
Oncology specialist Biodexa inked a compelling licensing deal to treat a serious disease, and BDRX stock popped sharply higher.
Is GDRX Stock a Buy After Major Plunge? 3 Analysts Weigh In on GoodRx.
Prescription drug price-comparison tool GoodRx is suffering major losses today. GDRX is down big after failing to beat earnings estimates.
AMD Stock Alert: 16 Things to Know About AMD’s New Processors
Advanced Micro Devices (AMD) stock is rising higher on Tuesday after announcing a new generation of Ryzen Embedded processors.
Lam Research Corporation Prepped for Growth Into Earnings
Lam Research stock will likely report another blowout quarter, thanks to strong demand for LRCX’s chips for memory and storage.
Micron Technology, Inc. (MU) Stock: Next Stop … $30?
There wasn’t much hope for Micron (MU), but the company has proven the critics wrong. And MU stock should benefit as supply/demand improves.
3 AI Stocks Paving Your Path to Seven-Figure Wealth
These AI wealth-building stocks to buy have shown increasing revenue visibility from AI-related products into 2025.
GoodRx News: What a GDRX Stock Downgrade Means for Investors
Shares of GDRX stock are taking a beating on Wednesday after the company received its first downgrade since the Amazon Pharmacy announcement.
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?
Biodexa Pharmaceuticals stock is up alongside heavy trading of BDRX after announcing positive news from a brain cancer treatment trial.
Why Is Durect (DRRX) Stock Down 64% Today?
Durect stock is taking a beating on Wednesday as DRRX investors react to results from a Phase 2b clinical trial of larsucosterol.
2 – 10 of 240 results
